Skip to main content
. 2021 Sep 27;10(10):2550. doi: 10.3390/cells10102550

Figure 8.

Figure 8

Repeated administration of Z-VAD-FMK, a pan-caspase inhibitor, completely prevents the development of CIPN following bortezomib treatment in mice. Bortezomib at 0.4 mg/kg or vehicle was administered i.p. on days 0, 2, 5, 7, 9, and 12. The mice received repeated i.p. administration of Z-VAD-FMK at 1 mg/kg, 30 min before each dose of BTZ. Data show the mean with S.E.M for 5 mice. V, vehicle; BTZ, bortezomib. ** p < 0.01 vs. V in V-treated mice. † p < 0.05, †† p < 0.01 vs. V in BTZ-treated mice.